Unnamed: 0,title,date,stock,sentiment
1318670.0,Why Vanda's Stock Is Trading Lower Today,2020-06-09 10:51:00-04:00,VNDA,negative
1318671.0,Vanda Pharmaceuticals shares are trading lower after Citigroup downgraded the stock from Buy to Neutral and announced a price target of $14 per share.,2020-06-09 08:51:00-04:00,VNDA,positive
1318672.0,"Citigroup Downgrades Vanda Pharmaceuticals to Neutral, Announces $14 Price Target",2020-06-09 07:46:00-04:00,VNDA,neutral
1318673.0,Vanda Pharma Reports Federal District Court Granted Co. Motion To Dismiss False Claims Act Suit Filed Against Co.,2020-05-20 17:20:00-04:00,VNDA,positive
1318674.0,"Vanda Pharma Highlights CEO Proposal On Clinical Trial Data Sharing Coronavirus, Remdesivir",2020-05-20 10:48:00-04:00,VNDA,positive
1318675.0,Vanda Pharmaceuticals Announces Agreement With FDA On Resubmission Of Application For HETLIOZ For The Treatment Of Patients With Smith-Magenis Syndrome,2020-05-13 07:02:00-04:00,VNDA,positive
1318676.0,Vanda Pharmaceuticals Q1 Sales $58.000M Beat $56.870M Estimate,2020-05-06 16:13:00-04:00,VNDA,neutral
1318677.0,"The Daily Biotech Pulse: FDA Nod For AstraZeneca, AbbVie-Allergan Deal Clears Antitrust Hurdle",2020-05-06 08:42:00-04:00,VNDA,positive
1318678.0,The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace,2020-05-03 08:45:00-04:00,VNDA,neutral
1318679.0,70 Biggest Movers From Yesterday,2020-04-17 04:53:00-04:00,VNDA,neutral
1318680.0,52 Stocks Moving In Thursday's Mid-Day Session,2020-04-16 12:58:00-04:00,VNDA,neutral
1318681.0,52 Stocks Moving In Thursday's Mid-Day Session,2020-04-16 12:57:00-04:00,VNDA,neutral
1318682.0,"The Daily Biotech Pulse: FDA Nod For UroGen, Novavax Coronavirus Vaccine To Enter Clinics, Soligenix Licenses Vaccine Adjuvant",2020-04-16 08:09:00-04:00,VNDA,neutral
1318683.0,33 Stocks Moving in Thursday's Pre-Market Session,2020-04-16 07:19:00-04:00,VNDA,neutral
1318684.0,Vanda Pharmaceuticals shares are trading higher after the company announced the enrollment of the first patient in the company's ODYSSEY trial. The company also announced the initiation of its CALYPSO program.,2020-04-15 16:33:00-04:00,VNDA,positive
1318685.0,"Vanda Pharmaceuticals Announces Initiation of ""CALYPSO"" to Study the Role of Genetic Variation in Coronavirus Infections in Collaboration With University of Washington Medicine",2020-04-15 16:17:00-04:00,VNDA,neutral
1318686.0,Vanda Pharma Reports Conducting ODYSSEY Trial With Northwell Health Related To Patients With Severe Coronavirus-Related Pneumonia,2020-04-15 16:05:00-04:00,VNDA,negative
1318687.0,"The Daily Biotech Pulse: FDA Nod For Pfizer, Vanda Forges Partnership For COVID-19 Drug Research, Neuronetics Pre-Announces Revenue Shortfall",2020-04-09 07:52:00-04:00,VNDA,neutral
1318688.0,Vanda Pharmaceuticals Inc. And The University of Illinois at Chicago Announce Partnership To Identify Novel Antivirals Against Coronavirus,2020-04-08 16:09:00-04:00,VNDA,positive
1318689.0,Vanda Pharma Reports Initiation Of ODYSSEY Study For Patients With Coronavirus,2020-04-02 13:43:00-04:00,VNDA,neutral
1318690.0,Vanda Pharma Shares Tick Higher On Volume Following Trader Circulation Of Mar. 30-Dated ClinicalTrials.gov Study Record Detail For 'A Study to Investigate the Efficacy of Tradipitant in Treating Severe or Critical COVID-19 Infection',2020-03-30 10:41:00-04:00,VNDA,negative
1318691.0,"The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection",2020-03-19 07:37:00-04:00,VNDA,neutral
1318692.0,"The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates",2020-03-18 07:36:00-04:00,VNDA,positive
1318693.0,"The Daily Biotech Pulse: Setback For DBV In Peanut Allergy Patch Review, Roche Starts Coronavirus Test Shipment, Regeneron Aims For 'Cocktail' COVID-19 Treatment",2020-03-17 08:48:00-04:00,VNDA,neutral
1318694.0,Stocks That Hit 52-Week Lows On Monday,2020-03-16 11:51:00-04:00,VNDA,negative
1318695.0,"Benzinga's Top Upgrades, Downgrades For March 12, 2020",2020-03-12 09:57:00-04:00,VNDA,positive
1318696.0,"Citigroup Upgrades Vanda Pharmaceuticals to Buy, Announces $14 Price Target",2020-03-12 05:44:00-04:00,VNDA,neutral
1318697.0,"The Daily Biotech Pulse: Mesoblast To Test Candidate On Coronavirus Symptoms, Proxy Battle Ahead For Rockwell Medical, Glaukos to Join S&P SmallCap 600 Index",2020-03-10 09:19:00-04:00,VNDA,negative
1318698.0,"The Daily Biotech Pulse: GenMark Diagnostics Ships COVID-19 Test Kits, Karyopharm To Offer Shares, And More",2020-03-03 07:51:00-05:00,VNDA,positive
1318699.0,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy",2020-02-27 07:35:00-05:00,VNDA,positive
1318700.0,Stocks That Hit 52-Week Lows On Wednesday,2020-02-26 11:14:00-05:00,VNDA,negative
1318701.0,"Stifel Maintains Hold on Vanda Pharmaceuticals, Lowers Price Target to $13",2020-02-26 10:25:00-05:00,VNDA,negative
1318702.0,"The Daily Biotech Pulse: Menlo Flunks Midstage Trial, GW Pharma's Earnings, COVID-19 Updates",2020-02-26 09:36:00-05:00,VNDA,negative
1318703.0,"JMP Securities Maintains Market Outperform on Vanda Pharmaceuticals, Lowers Price Target to $25",2020-02-26 09:31:00-05:00,VNDA,positive
1318704.0,Vanda Pharmaceuticals Shares Resume Trade,2020-02-25 16:41:00-05:00,VNDA,positive
1318705.0,Vanda Pharma Shares To Resume Trade At 4:40 p.m. EST,2020-02-25 16:17:00-05:00,VNDA,positive
1318706.0,Vanda Pharma Shares To Resume Trade At 4:40 p.m. EST,2020-02-25 16:17:00-05:00,VNDA,positive
1318707.0,Vanda Announces Results From EPIONE Study; Tradipitant Antipruritic Effects Not Seen In Moderate Or Severe Atopic Dermatitis And The Study Did Not Meet Its Primary Endpoint,2020-02-25 16:14:00-05:00,VNDA,negative
1318708.0,"Vanda Pharma Sees FY20 Sales $240M-$260M vs $274.6M Estimate, Year-End Cash $320M+",2020-02-25 16:09:00-05:00,VNDA,neutral
1318709.0,"Vanda Pharmaceuticals Q4 EPS $0.08 Misses $0.11 Estimate, Sales $60.93M Beat $59.57M Estimate",2020-02-25 16:04:00-05:00,VNDA,negative
1318710.0,Vanda Shares Halted News Pending,2020-02-25 16:03:00-05:00,VNDA,positive
1318711.0,"The Daily Biotech Pulse: Moderna Ships COVID-19 Vaccine For Clinics, Mallinckrodt Strikes $1.6B Opioid Settlement",2020-02-25 08:28:00-05:00,VNDA,negative
1318712.0,The Week Ahead In Biotech: Biopharma Earnings Pick Up Pace,2020-02-23 18:38:00-05:00,VNDA,neutral
1318713.0,Vanda Pharmaceuticals Option Alert: Mar 20 $16 Calls at the Ask: 1000 @ $1.101 vs 230 OI; Earnings 2/12 After Close [est] Ref=$15.1,2020-01-21 12:41:00-05:00,VNDA,positive
1318714.0,"Vanda Pharmaceuticals Wins U.S. Supreme Court Patent Ruling On Fanapt; Order By U.S. Supreme Court Ensures That '610 Patent Will Remain Exclusive At Least Through November 2, 2027",2020-01-13 14:16:00-05:00,VNDA,positive
1318715.0,"Week Ahead In Biotech: PDUFA Date Ahead For Astra Zeneca, Merck's Lynparza, Pending Clinical Readouts In Focus",2019-12-29 18:38:00-05:00,VNDA,neutral
1318716.0,94 Biggest Movers From Yesterday,2019-11-08 06:01:00-05:00,VNDA,neutral
1318717.0,75 Stocks Moving In Thursday's Mid-Day Session,2019-11-07 12:19:00-05:00,VNDA,neutral
1318718.0,"The Daily Biotech Pulse: Obseva Sinks On Adverse Clinical Readout, BioNano Surges On Saphyr Adoption, 2 IPOs",2019-11-07 07:18:00-05:00,VNDA,negative
1318719.0,"Vanda Pharma Reaffirms 2019 Net Product Sales Guidance, Says it Expects Results in the Upper Half of its Previously Given Range",2019-11-06 16:42:00-05:00,VNDA,neutral
1318720.0,"Vanda Pharmaceuticals Q3 EPS $0.23 Beats $0.07 Estimate, Sales $59.485M Beat $58.32M Estimate",2019-11-06 16:41:00-05:00,VNDA,neutral
1318721.0,"The Daily Biotech Pulse: Sesen Rallies On Positive FDA Meeting, Supernus Flunks Late-Stage ADHD Trial, GW Pharma Earnings",2019-11-06 08:21:00-05:00,VNDA,positive
1318722.0,Vanda Pharma Offers Results Of Comparative Genomics Study Presented At American Society of Human Genetics Conference,2019-10-23 16:05:00-04:00,VNDA,neutral
1318723.0,Attention Biotech Investors: Mark Your Calendar For These September PDUFA Dates,2019-08-28 08:02:00-04:00,VNDA,neutral
1318724.0,FDA Issues Complete Response For Vanda's Hetlioz In Jet Lag Disorder,2019-08-19 10:06:00-04:00,VNDA,negative
1318725.0,33 Healthcare Stocks Moving In Monday's Pre-Market Session,2019-08-19 08:47:00-04:00,VNDA,neutral
1318726.0,27 Stocks Moving in Monday's Pre-Market Session,2019-08-19 08:12:00-04:00,VNDA,neutral
1318727.0,Adam Feuerstein Tweet: FDA finally realizes$VNDA is peddling cheap melatonin as an ultra-expensive branded drug. Long overdue,2019-08-19 07:07:00-04:00,VNDA,neutral
1318728.0,"Vanda Pharma Receives a Complete Response Letter from the FDA for HETLIOZ in the Treatment of Jet Lag Disorder, FDA Says Vanda's Study is of Unclear Clinical Significance",2019-08-19 07:02:00-04:00,VNDA,negative
1318729.0,Biotech Stock On The Radar: Is Vanda A Buy Ahead Of Its PDUFA Date?,2019-08-13 15:23:00-04:00,VNDA,neutral
1318730.0,"The Week Ahead In Biotech: Vanda Awaits FDA Decision, BioVie Plans IPO",2019-08-11 15:46:00-04:00,VNDA,positive
1318731.0,100 Biggest Movers From Yesterday,2019-08-02 05:53:00-04:00,VNDA,neutral
1318732.0,72 Stocks Moving In Thursday's Mid-Day Session,2019-08-01 12:16:00-04:00,VNDA,neutral
1318733.0,"Citi Upgrades Vanda Pharmaceuticals to Buy, Announces $19 Price Target",2019-08-01 07:22:00-04:00,VNDA,neutral
1318734.0,"The Daily Biotech Pulse: Exelixis Signs Cancer Drug Licensing Deal, Adamis Offering, Surmodics Surges On Earnings",2019-08-01 07:18:00-04:00,VNDA,negative
1318735.0,28 Healthcare Stocks Moving In Wednesday's After-Market Session,2019-08-01 04:20:00-04:00,VNDA,neutral
1318736.0,Attention Biotech Investors: Mark Your Calendar For These August PDUFA Dates,2019-07-31 17:15:00-04:00,VNDA,neutral
1318737.0,"The Daily Biotech Pulse: Roche-Spark Deal Faces Further Delay, Bayer's Prostate Cancer Drug Passes FDA Muster",2019-07-31 07:06:00-04:00,VNDA,negative
1318738.0,"The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate",2019-07-27 14:32:00-04:00,VNDA,negative
1318739.0,10 Biggest Price Target Changes For Thursday,2019-07-25 09:29:00-04:00,VNDA,neutral
1318740.0,"Stifel Nicolaus Downgrades Vanda Pharmaceuticals to Hold, Lowers Price Target to $17",2019-07-25 06:37:00-04:00,VNDA,negative
1318741.0,"The Daily Biotech Pulse: Acadia Schizophrenia Drug Fails, Viveve Plummets, Eisai Gets Breakthrough Therapy Designation",2019-07-23 07:26:00-04:00,VNDA,negative
1318742.0,Vanda Pharmaceuticals Reports FDA Has Identified Deficiencies That Preclude Discussion Of Labeling And Postmarketing Requirements/Commitments Of HETLIOZ At This Time,2019-07-22 07:19:00-04:00,VNDA,neutral
1318743.0,Vanda Pharma Reports Tradipitant Was Effective In Treating Motion Sickness In Study Conducted In Pacific Ocean,2019-07-16 16:19:00-04:00,VNDA,positive
1318744.0,"The Daily Biotech Pulse: Nuvectra Files For Expanded Label For Algovita SCS, Axovant Earnings, FDA Nod For Aratana",2019-06-12 07:34:00-04:00,VNDA,neutral
1318745.0,"Vanda Pharma 8-K Shows US Dept. Of Justice Reviewed Amended Complaint, Reaffirmed Decision Not To Intervene In Qui Tam Action",2019-06-10 16:36:00-04:00,VNDA,positive
1318746.0,"'$VNDA amended Qui Tam complaint now unsealed.  Three new whistleblowers allege illegal activity at the company including a former sales manager, sales rep, and unidentified current employee.  Documents now live:...' -Tweets Aurelius Value",2019-06-10 12:57:00-04:00,VNDA,negative
1318747.0,"Vanda Pharmaceuticals Q1 EPS $(0.01) Misses $0.07 Estimate, Sales $47.713M Miss $51.76M Estimate",2019-05-01 16:33:00-04:00,VNDA,negative
1318748.0,"The Daily Biotech Pulse: Nabriva Stumbles At FDA Hurdle, Gilead CFO To Retire, Eisai Ends Collaboration With Purdue",2019-05-01 07:39:00-04:00,VNDA,neutral
1318749.0,31 Stocks Moving In Friday's Pre-Market Session,2019-02-15 08:20:00-05:00,VNDA,neutral
1318750.0,71 Biggest Movers From Yesterday,2019-02-15 04:59:00-05:00,VNDA,neutral
1318751.0,52 Stocks Moving In Thursday's Mid-Day Session,2019-02-14 12:27:00-05:00,VNDA,neutral
1318752.0,"The Daily Biotech Pulse: Vanda Q4 Results, Inovio Debt Offering, Caladrius Diabetes Drug Flunks Mid-Stage Trial",2019-02-14 07:50:00-05:00,VNDA,negative
1318753.0,Vanda Pharmaceuticals Sees FY19 Sales $215M-$225M vs $246.66M Est.,2019-02-13 16:10:00-05:00,VNDA,neutral
1318754.0,"Vanda Pharmaceuticals Q4 Adj. EPS $0.26 May Not Compare To $0.01 Estimate, Sales $53.04M Beat $51.7M Estimate",2019-02-13 16:08:00-05:00,VNDA,neutral
1318755.0,"The Daily Biotech Pulse: Exelixis Q4 Results, FDA Panel Greenlights J&J's Depression Drug, MacroGenics Prices Offering",2019-02-13 07:49:00-05:00,VNDA,negative
1318756.0,"Vanda Pharma Shares Fall To Session Low, Down 4%, As Traders Circulate Word Of Short Call From Aurelius Value",2019-02-11 10:02:00-05:00,VNDA,positive
1318757.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials",2019-02-10 17:37:00-05:00,VNDA,neutral
1318758.0,62 Biggest Movers From Yesterday,2019-02-07 04:19:00-05:00,VNDA,neutral
1318759.0,48 Stocks Moving In Wednesday's Mid-Day Session,2019-02-06 12:18:00-05:00,VNDA,neutral
1318760.0,Vanda Pharmaceuticals shares are trading lower after Cantor Fitzgerald downgraded the stock from overweight to neutral.,2019-02-06 09:40:00-05:00,VNDA,negative
1318761.0,33 Stocks Moving In Wednesday's Pre-Market Session,2019-02-06 08:27:00-05:00,VNDA,neutral
1318762.0,"The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering",2019-02-06 08:23:00-05:00,VNDA,neutral
1318763.0,Cantor Fitzgerald Downgrades Vanda Pharmaceuticals to Neutral,2019-02-06 07:41:00-05:00,VNDA,neutral
1318764.0,Vanda Pharmaceuticals Files Complaint Against FDA For Requiring Studies In  Animals Without Legal Authority,2019-02-05 17:08:00-05:00,VNDA,negative
1318765.0,Vanda Pharma Reports FDA Accepted HETLIOZ Supplemental New Drug Application For Review In Treatment Of Jet Lag Disorder,2018-12-20 07:16:00-05:00,VNDA,negative
1318766.0,"Oppenheimer Downgrades Vanda Pharmaceuticals to Perform, Announces $29 Price Target",2018-12-11 08:32:00-05:00,VNDA,neutral
1318767.0,Vanda Pharma's HETLIOX Met 1 of 2 Primary Endpoints,2018-12-10 07:07:00-05:00,VNDA,neutral
1318768.0,"JMP Securities Maintains Market Outperform on Vanda Pharmaceuticals, Raises Price Target to $52",2018-12-06 08:08:00-05:00,VNDA,positive
1318769.0,"Benzinga's Top Upgrades, Downgrades For December 4, 2018",2018-12-04 10:21:00-05:00,VNDA,positive
1318770.0,"Stocks Which Set New 52-Week High Yesterday, Mon., Dec. 3, 2018",2018-12-04 09:20:00-05:00,VNDA,neutral
1318771.0,"The Daily Biotech Pulse: ASH Presentations Take The Spotlight, Eiger Gets A New CFO",2018-12-04 07:59:00-05:00,VNDA,neutral
1318772.0,"Cantor Fitzgerald Upgrades Vanda Pharmaceuticals to Overweight, Announces $43 Price Target",2018-12-04 06:39:00-05:00,VNDA,negative
1318773.0,56 Biggest Movers From Yesterday,2018-12-04 05:02:00-05:00,VNDA,neutral
1318774.0,46 Stocks Moving In Monday's Mid-Day Session,2018-12-03 12:37:00-05:00,VNDA,neutral
1318775.0,Vanda Pharma shares are trading higher after the company's phase 2 study of Tradipitant met its primary endpoint and most secondary endpoints.,2018-12-03 08:28:00-05:00,VNDA,positive
1318776.0,"Vanda Pharma's Phase 2 Study for Tradipitant in Patients with Gastroparesis Met its Primary Endpoint, 'Most' Secondary Endpoints",2018-12-03 06:05:00-05:00,VNDA,neutral
1318777.0,80 Biggest Movers From Yesterday,2018-11-09 05:18:00-05:00,VNDA,neutral
1318778.0,65 Stocks Moving In Thursday's Mid-Day Session,2018-11-08 12:51:00-05:00,VNDA,neutral
1318779.0,"Jefferies Initiates Coverage On Vanda Pharmaceuticals with Buy Rating, Announces $26 Price Target",2018-11-08 10:18:00-05:00,VNDA,neutral
1318780.0,Vanda Pharmaceuticals Maintains FY2018 Sales Guidance of $180.0M-200.0M vs $192.44M Est,2018-11-07 16:32:00-05:00,VNDA,neutral
1318781.0,"Vanda Pharmaceuticals Inc. Q3 EPS $0.13 Beats $(0.02) Estimate, Sales $49.135M Miss $49.44M Estimate",2018-11-07 16:31:00-05:00,VNDA,negative
1318782.0,"The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie",2018-11-07 07:50:00-05:00,VNDA,negative
1318783.0,"The Week Ahead In Biotech: Earnings, Conferences, PDUFA Dates, Clinical Trial Results And IPOs",2018-11-04 13:35:00-05:00,VNDA,neutral
1318784.0,Vanda Reports FDA Sent Letter To Co. Related To 1 Page Of Its Corporate Website; Says Co. Modified Content On This Page,2018-11-01 09:41:00-04:00,VNDA,neutral
1318785.0,"Vanda Pharma Shares Down 2.2%; Traders Circulating Word Of Cautious Comments Related To FDA Warning Letter, Source Of Comments Is Not Clear",2018-10-31 09:41:00-04:00,VNDA,negative
1318786.0,"Stocks Which Set New 52-Week High Yesterday, September 26th",2018-09-27 09:12:00-04:00,VNDA,neutral
1318787.0,41 Biggest Movers From Yesterday,2018-09-27 05:01:00-04:00,VNDA,neutral
1318788.0,30 Stocks Moving In Wednesday's Mid-Day Session,2018-09-26 12:32:00-04:00,VNDA,neutral
1318789.0,"The Daily Biotech Pulse: Verastem's Chinese Duvelisib Licensing Deal, Aldeyra's Positive Dry Eye Disease Drug Trial",2018-09-26 08:25:00-04:00,VNDA,positive
1318790.0,28 Stocks Moving In Wednesday's Pre-Market Session,2018-09-26 08:03:00-04:00,VNDA,neutral
1318791.0,UPDATE: Vanda Pharma To Replace Inogen In S&P SmallCap 600,2018-09-25 17:22:00-04:00,VNDA,neutral
1318792.0,"S&P Dow Jones Indices Reports Rollins Will Join S&P 500, Inogen To Join S&P MidCap 400, Vanda, Garrett Motion To Join S&P SmallCap 600",2018-09-25 17:21:00-04:00,VNDA,positive
1318793.0,Vanda Announces Listing Of A New HETLIOZ Patent In FDA Orange Book; Patent Was Announced On Sept 11,2018-09-20 17:10:00-04:00,VNDA,neutral
1318794.0,"Stifel Nicolaus Initiates Coverage On Vanda Pharmaceuticals with Buy Rating, Announces $30 Price Target",2018-09-14 07:06:00-04:00,VNDA,neutral
1318795.0,Vanda Pharmaceuticals Announces HETLIOZ Driving Study Demonstrates No Impairment in Next Morning Performance,2018-09-12 19:02:00-04:00,VNDA,negative
1318796.0,"Cantor Fitzgerald Initiates Coverage On Vanda Pharmaceuticals with Neutral Rating, Announces $26 Price Target",2018-08-23 07:09:00-04:00,VNDA,neutral
1318797.0,Vanda Pharma Wins Denial of Petition For Rehearing on Fanapt,2018-08-14 16:45:00-04:00,VNDA,positive
1318798.0,"Stocks Which Set New 52-Week High Yesterday, August 8th",2018-08-09 11:03:00-04:00,VNDA,neutral
1318799.0,"Stocks Which Set New 52-Week High Yesterday, August 7th",2018-08-08 11:01:00-04:00,VNDA,neutral
1318800.0,"The Daily Biotech Pulse: FDA Panel Backs Insmed, Eidos' Maiden Earnings, Paratek Awaits Adcom Verdict",2018-08-08 08:15:00-04:00,VNDA,positive
1318801.0,"Stocks Which Set New 52-Week High Yesterday, August 2nd",2018-08-03 11:16:00-04:00,VNDA,neutral
1318802.0,"The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings",2018-08-03 07:52:00-04:00,VNDA,neutral
1318803.0,"The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter",2018-08-02 08:54:00-04:00,VNDA,positive
1318804.0,Vanda Pharma Sees FY18 HETLIOZ and Fanapt Combined Sales $180M-$200M,2018-08-01 16:05:00-04:00,VNDA,neutral
1318805.0,"Vanda Pharmaceuticals Q2 Adj. EPS $0.15 Beats $(0.18) Estimate, Sales $47.35M Beat $47.28M Estimate",2018-08-01 16:04:00-04:00,VNDA,neutral
1318806.0,"Benzinga's Biotech Pulse: Pfizer's Xeljanz Gets EU Nod, NewLink Losses Narrow, Neuralstem Commences Stroke Drug Trial",2018-08-01 09:01:00-04:00,VNDA,negative
1318807.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs",2018-07-28 14:04:00-04:00,VNDA,neutral
1318808.0,Stocks Which Set New 52-Week High Yesterday,2018-07-20 09:05:00-04:00,VNDA,neutral
1318809.0,"Benzinga's Daily Biotech Pulse: Novartis Licenses Skin Drug, 2 Stocks To Debut",2018-07-19 09:14:00-04:00,VNDA,neutral
1318810.0,Citigroup Earlier Initiated Coverage On Vanda Pharmaceuticals with Buy Rating,2018-05-23 10:34:00-04:00,VNDA,neutral
1318811.0,Vanda Pharma Reports Results From JET Study Of HETLIOZ Which Showed Effectiveness In Treating Jet Lag Disorder In Travelers Who Flew From US To UK,2018-05-23 08:09:00-04:00,VNDA,negative
1318812.0,Vanda Pharmaceuticals Reaffirms FY2018 Sales $180.0M-200.0M vs $187.40M Est,2018-05-02 16:54:00-04:00,VNDA,neutral
1318813.0,"Vanda Pharmaceuticals Q1 EPS $0.14 May Not Compare To $(0.14) Estimate, Sales $43.592M Beat $42.98M Estimate",2018-05-02 16:53:00-04:00,VNDA,neutral
1318814.0,"Benzinga's Daily Biotech Pulse: SIGA Rallies On FDA Panel Backing, Rigel And Gilead React To Earnings",2018-05-02 07:41:00-04:00,VNDA,neutral
1318815.0,"Vanda Wins Appeal Case on Fanapt, U.S. Court of Appeals Affirms District Court's Decision",2018-04-13 12:01:00-04:00,VNDA,positive
1318816.0,"Teva Submits an NDA to the FDA Requesting Approval to Market Generic HETLIOZ, Says 6 of Vanda Pharma's Patents Which Expire in 2034 are Unenforceable",2018-03-26 07:07:00-04:00,VNDA,positive
1318817.0,Vanda Pharmaceuticals Shares Down 6.1%  After Co. Priced 5.5M Share Common Stock Offering At $17/Share,2018-03-16 12:11:00-04:00,VNDA,positive
1318818.0,Vanda Pharmaceuticals Prices 5.5M Share Public Offering of Common Stock @$17/Share,2018-03-16 04:09:00-04:00,VNDA,positive
1318819.0,Vanda Pharmaceuticals Proposes Common Stock Offering,2018-03-14 16:01:00-04:00,VNDA,neutral
1318820.0,Vanda Pharma's HETLIOZ Demonstrates Efficacy to Treat Jet Lag Disorder in an 8 Hour Phase Advance Clinical Study,2018-03-05 07:21:00-05:00,VNDA,negative
1318821.0,Vanda Pharma Sees FY18 Combined Sales of $180M-$200M,2018-02-14 16:04:00-05:00,VNDA,neutral
1318822.0,"Vanda Pharma Reports Q4 Ad.j EPS $0.03 May Not Compare To $(0.12) Est., Sales $44.276M vs $43.45M Est.",2018-02-14 16:03:00-05:00,VNDA,neutral
1318823.0,Vanguard Group Reports 6.3% Stake In Vanda Pharmaceuticals,2018-02-09 11:51:00-05:00,VNDA,neutral
1318824.0,"Seaport Global Initiates Coverage On Vanda Pharmaceuticals with Buy Rating, Announces $20.00 Price Target",2018-01-19 10:10:00-05:00,VNDA,neutral
1318825.0,"5 Stocks To Watch For January 8, 2018",2018-01-08 05:57:00-05:00,VNDA,neutral
1318826.0,Vanda Pharmaceuticals Reports Preliminary FY17 Revenue ~$165M vs $164.16M Est; Preliminary FY18 Revenue $180M-$200M vs $193.2M Est,2018-01-07 09:25:00-05:00,VNDA,neutral
1318827.0,7 Notable Biotechs With Data Expected By Year's End,2017-12-29 15:16:00-05:00,VNDA,neutral
1318828.0,Oppenheimer's Top Stock Picks For December,2017-11-30 10:17:00-05:00,VNDA,positive
1318829.0,Vanda Receives Negative Opinion for Marketing Authorization from the European Medicines Agency on Fanaptum for the Treatment of Schizophrenia,2017-11-10 16:06:00-05:00,VNDA,negative
1318830.0,Vanda Pharmaceuticals Sees Q4 Combined Product Sales $42M-$48M; FY17 Combined Product Sales Cut From $165M-$175M to $163M-$169M,2017-11-07 16:40:00-05:00,VNDA,negative
1318831.0,"Vanda Pharma Reports Q3 EPS $(0.10) vs $(0.11) Est., Sales $41.336M vs $43.92M Est.",2017-11-07 16:39:00-05:00,VNDA,neutral
1318832.0,"Vanda Pharma Shares Up 7% Following Price Target Increase From $21 To $26 By Oppenheimer, Firm Cited More Favorable Forecasts For Hetlioz",2017-10-30 11:19:00-04:00,VNDA,positive
1318833.0,Benzinga's Option Alert Recap From October 26,2017-10-26 16:35:00-04:00,VNDA,positive
1318834.0,Vanda Pharma Option Alert: Dec 15 $14 Puts Sweep (22) at the Bid: 1000 @ $0.7 vs 142 OI; Ref=$14.475,2017-10-26 12:18:00-04:00,VNDA,positive
1318835.0,Vanda Pharmaceuticals Reaches Pricing Agreement With German National Association Of Statutory Health Insurance Funds,2017-10-18 07:07:00-04:00,VNDA,positive
1318836.0,29 Top Stock Ideas For October And Beyond,2017-10-16 15:29:00-04:00,VNDA,positive
1318837.0,"Vanda Pharma Shares Were Halted Ahead Of Tadipitant News, Now Resuming Trade",2017-09-13 16:31:00-04:00,VNDA,positive
1318838.0,"Vanda Pharma Reports Tradipitant Improved Itch, Disease Severity In Patients With Atopic Dermatitis",2017-09-13 16:07:00-04:00,VNDA,positive
1318839.0,Oppenheimer Presents New Menu Of Top Picks,2017-09-01 11:59:00-04:00,VNDA,positive
1318840.0,"Vanda Pharmaceuticals Reports EPS $0.03 vs $(0.28) Est., Sales $42.1M vs $40.31M Est.",2017-08-02 16:42:00-04:00,VNDA,neutral
1318841.0,Vanda Receives Negative Opinion for Marketing Authorization from the EMA on Fanaptum,2017-07-21 07:06:00-04:00,VNDA,negative
1318842.0,Oppenheimer Analysts Release 28 Best Ideas List,2017-06-29 13:24:00-04:00,VNDA,positive
1318844.0,13G Filing Shows Armistice Capital Reporting 5.1% Stake In Vanda Pharmaceuticals,2017-06-19 16:26:00-04:00,VNDA,neutral
1318845.0,"Benzinga's Top Upgrades, Downgrades For May 26, 2017",2017-05-26 09:31:00-04:00,VNDA,positive
1318846.0,"H.C. Wainwright Initiates Coverage On Vanda Pharmaceuticals with Buy Rating, Announces $18.00 Price Target",2017-05-26 07:23:00-04:00,VNDA,neutral
1318847.0,"Vanda Pharmaceuticals Reports Q1 EPS $(0.17) vs $(0.19) Est., Sales $37.415M vs $38.28M Est.",2017-05-02 16:50:00-04:00,VNDA,neutral
1318848.0,Oppenheimer Initiates Coverage On Vanda Pharmaceuticals With Outperform,2017-04-12 09:20:00-04:00,VNDA,neutral
1318849.0,Your Cheat Sheet For Q1 Biotech Earnings,2017-04-06 12:47:00-04:00,VNDA,negative
1318850.0,"Vanda Pharmaceuticals to Acquire Exclusive Worldwide License from UCSF to Develop, Commercialize Portfolio of CFTR Activators and Inhibitors for $1M Initially; Up to $46M in Milestones",2017-03-29 17:47:00-04:00,VNDA,negative
1318851.0,13G Filing Shows Point72 Asset Management 5% Stake In Vanda Pharmaceuticals,2017-02-16 16:46:00-05:00,VNDA,positive
1318852.0,Vanda Pharmaceuticals Sees FY17 Rev. $165-$175M vs. $168.6M,2017-02-15 16:36:00-05:00,VNDA,neutral
1318853.0,"Vanda Pharmaceuticals Reports Q4 EPS $(0.01) vs. $(0.09) Est., Rev. $38.24M vs. $38.39M Est.",2017-02-15 16:35:00-05:00,VNDA,neutral
1318854.0,20 Biggest Mid-Day Gainers For Wednesday,2017-02-08 12:34:00-05:00,VNDA,neutral
1318855.0,25 Stocks Moving In Wednesday's Pre-Market Session,2017-02-08 08:28:00-05:00,VNDA,neutral
1318856.0,Vanda Pharmaceuticals Trading Up 7.3% Premarket,2017-02-08 07:51:00-05:00,VNDA,neutral
1318857.0,"Vanda Pharmaceuticals Reports FY16 Prelim Rev. ~$146M vs. Est. $147M, FY17 Rev. $165-$175M vs. Est. $183M",2017-01-09 07:08:00-05:00,VNDA,neutral
1318858.0,"13F from Paulson & Co. Shows Increased Stake in Loxo Oncology, New Stake in Monster Worldwide, Steris, Talend, Tobira Therapeutics, Reduced Stakes in Pfizer, Puma Biotech, Synergy Pharma, Vanda, Liquidated Stake in Rite Aid",2016-11-14 17:54:00-05:00,VNDA,positive
1318859.0,Benzinga's Top Initiations,2016-11-09 09:21:00-05:00,VNDA,positive
1318860.0,Vanda Sees FY16 Rev. $143-$153M vs. Est. $147M,2016-11-02 16:04:00-04:00,VNDA,neutral
1318861.0,"Vanda Pharmaceuticals Reports Q3 EPS $(0.01) vs. Est. $(0.11), Rev. $38.48M vs. Est. $38.05M",2016-11-02 16:03:00-04:00,VNDA,neutral
1318862.0,"Vanda Pharmaceuticals Settles Fanapt Patent Litigation with Taro, Grants Taro License To Sell Generic Fanapt Beginning Nov. 2027",2016-10-24 16:04:00-04:00,VNDA,neutral
1318863.0,"Vanda's Fanapt, Pipeline Getting In Rhythm With Hetlioz; Jefferies Assumes At Buy",2016-10-06 12:43:00-04:00,VNDA,neutral
1318864.0,Jefferies Assumes Vanda Pharmaceuticals at Buy,2016-10-06 07:16:00-04:00,VNDA,neutral
1318865.0,"22 Stocks Which Rallied Four Days, Then Sold Off Yesterday",2016-09-28 09:15:00-04:00,VNDA,neutral
1318866.0,The Market In 5 Minutes: Indexes Looking To Close Week Higher,2016-09-23 09:04:00-04:00,VNDA,neutral
1318867.0,"Vanda Shares Spiking Higher, In Talks With Investment Banks To Hire Financial Adviser To Explore Options",2016-09-22 15:44:00-04:00,VNDA,positive
1318868.0,USPTO Dismisses Petition For IPR Of Fanapt Patent,2016-08-30 15:01:00-04:00,VNDA,neutral
1318869.0,Vanda Pharma Spikes to High of $15.08 on Volume,2016-08-26 15:27:00-04:00,VNDA,neutral
1318870.0,Watch These 7 Huge Call Purchases In Friday Trade,2016-08-26 01:10:00-04:00,VNDA,positive
1318871.0,Vanda Patents Found Valid and Infringed in Fanapt ANDA Litigation,2016-08-25 15:00:00-04:00,VNDA,negative
1318872.0,"PiperJaffray Maintains Overweight on Vanda Pharmaceuticals, Raises PT to $19.00, Positive On Upside Potential",2016-08-25 14:35:00-04:00,VNDA,positive
1318873.0,18 Biggest Mid-Day Gainers For Thursday,2016-08-25 12:55:00-04:00,VNDA,neutral
1318874.0,"Vanda Shares Spiking Higher, Hearing Cout Finds Roxane's Proposed Product Induces Infringement On Vanda's '610 Fanapt Patent",2016-08-25 11:43:00-04:00,VNDA,negative
1318875.0,Vanda Pharma Spikes to High of $14.30 on Volume,2016-08-25 11:39:00-04:00,VNDA,neutral
1318876.0,Option Alert: VNDA Sep16 12.0 Calls Sweep: 525 @  ASK  $1.95: 1482 traded vs 151 OI: $13.21 Ref,2016-08-25 11:37:00-04:00,VNDA,positive
1318877.0,Watch These 7 Huge Call Purchases In Thursday Trade,2016-08-11 02:57:00-04:00,VNDA,positive
1318878.0,Option Alert: VNDA Nov16 13.0 Calls: 1250 @  Above Ask!  $1.50: 2500 traded vs 0 OI: $12.30 Ref,2016-08-10 10:10:00-04:00,VNDA,positive
1318879.0,"Vanda Pharmaceuticals Reports Q2 EPS $(0.11) vs. Est. $(0.23), Rev. $36.02M vs. Est. $36.03M",2016-07-27 17:26:00-04:00,VNDA,neutral
1318880.0,A Peek Into The Markets: U.S. Stock Futures Rise; Fed Decision In Focus,2016-06-15 07:47:00-04:00,VNDA,neutral
1318881.0,Vanda Gets FDA Approval For Fanapt Marketing Exclusivity,2016-06-15 07:37:00-04:00,VNDA,positive
1318882.0,Vanda Pharma Reports FDA Has Granted Fanapt Three Years of Marketing Exclusivity for Labeling changes Related to Maintenance Treatment of Schizophrenia,2016-06-15 07:05:00-04:00,VNDA,positive
1318883.0,15 Stocks Moving In Friday's Pre-Market Session,2016-05-27 08:17:00-04:00,VNDA,neutral
1318884.0,Vanda Reports FDA Approval of the Fanapt Supplemental New Drug Application for Maintenance Treatment of Schizophrenia in Adults,2016-05-26 16:30:00-04:00,VNDA,positive
1318885.0,"Vanda Pharma Reaffirms FY16 Combined Product Sales of HETLIOZ, Fanapt $143M-$153M vs $148M Est.",2016-05-04 17:17:00-04:00,VNDA,neutral
1318886.0,"Vanda Pharma Reports Q1 Adj. EPS $(0.17) vs $(0.24) Est., Sales $33.262M vs $32.6M Est.",2016-05-04 17:17:00-04:00,VNDA,neutral
1318887.0,Option Alert: VNDA Jan17 10.0 Calls Sweep: 644 @  ASK  $1.75: 646 traded vs 145 OI:  Earnings 5/4 After Close  $9.32 Ref,2016-04-21 13:40:00-04:00,VNDA,positive
1318888.0,"Vanda Announces US District Court for the District of Delaware Scheduled Dive-day Bench Trial Beginning May 15, 2017 at Which Patent Lawsuits Would be Tried Together",2016-04-04 07:06:00-04:00,VNDA,negative
1318889.0,"Vanda Pharmaceuticals Reports Q4 EPS $(0.23) vs. Est. $(0.26), Rev. $31.8M vs. Est. $31.34M",2016-02-10 16:03:00-05:00,VNDA,neutral
1318890.0,Vanda Pharmaceuticals Sees Q4 Sales $31.80M vs $30.80M Est,2016-01-11 06:58:00-05:00,VNDA,neutral
1318891.0,Vanda Pharmaceuticals Sees FY2016 Sales $143.0M-153.0M vs $146.50M Est,2016-01-11 06:57:00-05:00,VNDA,neutral
1318892.0,Vanda Pharmaceuticals Sees FY2015 Sales $109.90M vs $108.90M Est,2016-01-11 06:56:00-05:00,VNDA,neutral
1318893.0,Vanda Pharma Reports EMA Has Accepted Fanaptum MAA for Treatment of Schizophrenia in Adults,2015-12-22 16:31:00-05:00,VNDA,positive
1318894.0,Vanda Pharmaceuticals Spikes to High,2015-12-09 13:03:00-05:00,VNDA,neutral
1318895.0,Mid-Morning Market Update: Markets Mostly Flat; Time Warner Beats Q3 Views,2015-11-04 10:11:00-05:00,VNDA,neutral
1318896.0,"Vanda Pharmaceuticals Reports Q3 EPS $(0.11) vs. Est. $(0.20), Rev. $28.3M vs. Est. $28.84M",2015-11-03 17:21:00-05:00,VNDA,neutral
1318897.0,Benzinga's Top Initiations,2015-10-21 10:01:00-04:00,VNDA,positive
1318898.0,"Brean Capital Initiates Coverage on Vanda Pharmaceuticals at Buy, Announces $20.00 PT",2015-10-21 05:23:00-04:00,VNDA,neutral
1318899.0,Vanda Pharma Reports Listing of New Fanapt Patent in FDA's Orange Book,2015-09-23 16:30:00-04:00,VNDA,neutral
1318900.0,Vanda Announces FDA Has Accepted for Review the Fanapt Supplemental New Drug Application for Maintenance Treatment of Schizophrenia in Adults,2015-09-15 07:01:00-04:00,VNDA,positive
1318901.0,Vanda Pharmaceuticals Announces Richard Gulino As General Counsel,2015-09-14 07:02:00-04:00,VNDA,neutral
1318902.0,Vanda Announces Favorable Markman Ruling in Fanapt® Patent Infringement Litigation,2015-09-10 07:31:00-04:00,VNDA,negative
1318903.0,Vanda Pharmaceuticals Announces Gian Piero Reverberi As European General Manager,2015-09-08 07:06:00-04:00,VNDA,neutral
1318904.0,"Vanda Pharmaceuticals Reports Q2 EPS $(0.13) vs. Est. $(0.29), Rev. $27.6M vs. Est. $24.55M",2015-07-29 17:31:00-04:00,VNDA,neutral
1318905.0,Vanda Pharma Announces European Commission Approval For Sleep Wake Disorder in the Totally Blind,2015-07-07 16:33:00-04:00,VNDA,negative
1318906.0,Vanda Pharma Announces Listing of New HETLIOZ Patent in FDA Orange Book,2015-07-02 09:02:00-04:00,VNDA,neutral
1318908.0,Netflix Goes 7-For-1; Vanda Pharma And FibroGen Lead Tuesday's After-Hours Movers,2015-06-23 17:32:00-04:00,VNDA,neutral
1318909.0,"Vanda Shares Rally $1+ Following News REPRIEVE Study Showed Ability of Fanapt to Prevent Relapse, Impending Relapse in Adults with Schizophrenia",2015-06-23 16:40:00-04:00,VNDA,positive
1318911.0,Label Restrictions Sought On Vanda Pharmaceuticals' Sleep Drug,2015-06-11 14:22:00-04:00,VNDA,neutral
1318912.0,WSJ Pharmalot Blog Posts: 'FDA Mistakenly Widened the Market for a Rare Sleep Disorder Drug: Petition',2015-06-11 11:09:00-04:00,VNDA,negative
1318913.0,Vanda Pharmaceuticals Spikes Higher on Heavy Volume,2015-05-15 14:41:00-04:00,VNDA,neutral
1318914.0,"Vanda pharma Reports Q1 EPS $(0.24) vs. Est. $(0.25), Rev. $22.2M vs. Est. $20.18M",2015-05-06 16:02:00-04:00,VNDA,neutral
1318915.0,EMA Recommends Approval of Vanda Pharmaceuticals' Tasimelteon for Non 24-Hour Sleep-Wake Disorder,2015-04-24 07:08:00-04:00,VNDA,positive
1318916.0,Vanda Pharmaceuticals Names Tom Gibbs as Chief Commercial Officer,2015-04-20 08:03:00-04:00,VNDA,neutral
1318917.0,"Vanda Reports Trial Date for Two Pending Fanapt Patent Cases as Feb. 29, 2016",2015-04-13 17:47:00-04:00,VNDA,neutral
1318918.0,Baker Bros Reduces Stake In Vanda Pharma From 10.74% To 4.2%,2015-04-10 17:34:00-04:00,VNDA,neutral
1318919.0,Vanda Announces Listing of New Fanapt Patent in FDA Orange Book,2015-04-10 04:37:00-04:00,VNDA,neutral
1318920.0,Vanda Reports Listing Of Fanapt Patent In FDA Orange Book,2015-04-09 09:16:00-04:00,VNDA,neutral
1318921.0,Option Alert: Vanda May $11 Call; 1500 Contract Trade at Ask @$0.65,2015-03-31 12:12:00-04:00,VNDA,positive
1318923.0,"Jefferies Initiates Coverage on Vanda Pharmaceuticals at Buy, Announces $20.00 PT",2015-03-09 05:53:00-04:00,VNDA,neutral
1318924.0,Vanda Pharma Announces Tradipitant Phase II Proof of Concept Study Results for Chronic Pruritus in Atopic Dermatits,2015-03-04 16:33:00-05:00,VNDA,neutral
1318925.0,"JMP Feeling Mostly Good On 4 Drug, Healthcare Stocks",2015-02-21 14:21:00-05:00,VNDA,positive
1318926.0,"Vanda Pharma Reports Q4 EPS Loss $0.36 Vs Est Loss $0.20, Sales $15.4M Vs Est $16.15M",2015-02-19 07:07:00-05:00,VNDA,negative
1318927.0,Option Alert: Vanda Pharmaceuticals Mar $16 Call; 1862 Contract Trade at $0.39; Now $12.11,2015-01-23 14:51:00-05:00,VNDA,positive
1318928.0,Vanda Reports Listing of New Fanapt Patent in FDA Orange Book,2015-01-16 09:32:00-05:00,VNDA,neutral
1318929.0,Option Alert: Vanda Feb $12 Call; 1784 Contract Trade at Ask @$1.25; Currently $11.98,2015-01-15 11:38:00-05:00,VNDA,positive
1318930.0,"Option Alert: Vanda Mar $13 Call; 5,008 Contracts Trade vs 4786 OI; Currently $12.08",2015-01-14 10:43:00-05:00,VNDA,positive
1318931.0,Option Alert: Vanda Pharmaceuticals Jan $12 Call; 3359 Contracts Traded vs 164 OI; Currently $12.84,2015-01-09 09:47:00-05:00,VNDA,positive
1318932.0,These Gainers Have Elevated Short Interest,2014-12-23 15:54:00-05:00,VNDA,positive
1318933.0,"Mid-Day Gainers From December 23: NQ Mobile, Vanda Pharmaceuticals, Smith & Nephew And More",2014-12-23 13:28:00-05:00,VNDA,neutral
1318934.0,Benzinga's Volume Movers,2014-12-23 10:47:00-05:00,VNDA,neutral
1318935.0,Mid-Morning Market Update: Markets Mostly Higher; Walgreen Profit Beats Expectations,2014-12-23 10:40:00-05:00,VNDA,positive
1318936.0,Morning Market Movers,2014-12-23 09:54:00-05:00,VNDA,neutral
1318937.0,"Tuesday's #PreMarket Movers: NQ Mobile, Cytokinetics, Walgreen And More",2014-12-23 09:23:00-05:00,VNDA,neutral
1318938.0,Benzinga's Top #PreMarket Gainers,2014-12-23 08:11:00-05:00,VNDA,positive
1318939.0,Vanda Pharmaceuticals And Novartis Settle License Dispute,2014-12-23 08:08:00-05:00,VNDA,negative
1318940.0,UPDATE: Vanda to Acquire Rights to Phase II Clinical Compound From Novartis,2014-12-22 16:04:00-05:00,VNDA,neutral
1318941.0,Novartis to Purchase $25M Og Vanda Common Stock,2014-12-22 16:03:00-05:00,VNDA,neutral
1318942.0,Vanda Pharma Prices 5M Shares at $11.60/Share,2014-10-29 09:01:00-04:00,VNDA,positive
1318943.0,Vanda Pharmaceuticals Inc. Proposes Public Offering of Common Stock ,2014-10-28 16:11:00-04:00,VNDA,neutral
1318944.0,Morning Market Movers ,2014-10-27 09:55:00-04:00,VNDA,neutral
1318945.0,Vanda Pharma Shares Surge 11-12% as Co. Reports Q3 EPS of $(0.04) vs $(0.39) Est; Revenue of $14.80M vs $12.20M Est,2014-10-27 09:25:00-04:00,VNDA,positive
1318946.0,Benzinga's Top #PreMarket Gainers,2014-10-27 08:17:00-04:00,VNDA,positive
1318947.0,"Option Alert: Vanda Parma Nov $13 Call; 1,313 Contact Trade at Ask @$0.55; Currently $10.77",2014-10-24 15:23:00-04:00,VNDA,positive
1318948.0,The 3 Most Volatile Biotech Stocks,2014-10-14 12:42:00-04:00,VNDA,neutral
1318949.0,"Option Alert: Vanda Pharma Oct $11 Call; 2,000 Contract Trade at Ask @$0.50; Currently $10.35",2014-10-06 09:57:00-04:00,VNDA,positive
1318950.0,The Wildest Biotech Stock Out There,2014-08-19 11:47:00-04:00,VNDA,neutral
1318951.0,Vanda Pharmaceuticals Inc. Reports Q2 EPS of $(0.64) vs $(0.73) Est; Revenue of $10.90M vs $10.0M Est,2014-08-07 07:10:00-04:00,VNDA,neutral
1318952.0,13G Filing from James Flynn and Deerfield Mgmt on Vanda Pharma Shows Raised 6.09% Stake ,2014-08-01 09:30:00-04:00,VNDA,neutral
1318953.0,"8-K from Vanda Pharma Shows Novartis is Counter-Claimant in Arbitration Proceeding, Expecting Closing or Proceeding in 12-18 Mos.",2014-07-17 08:26:00-04:00,VNDA,neutral
1318954.0,3 Small-Cap Biotechs That Institutions Are Loving,2014-07-07 14:54:00-04:00,VNDA,positive
1318955.0,"8-K from Vanda Pharma Shows Suit Against Roxane Labs Filed, Seeking Adjudication on Alleged Patent Infringement",2014-06-16 07:04:00-04:00,VNDA,negative
1318956.0,"Empire Asset Management Initiates Coverage on Vanda Pharmaceuticals Inc. at Sell, Announces $6.00 PT",2014-06-10 09:56:00-04:00,VNDA,positive
1318957.0,Vanda Pharmaceuticals Moves Higher on Volume,2014-06-06 12:38:00-04:00,VNDA,neutral
1318958.0,Vanda Shares Jumped 29% Amid Continued Success Of Hetlioz,2014-06-05 10:56:00-04:00,VNDA,positive
1318959.0,"Mid-Day Market Movers For Wednesday, June 4, 2014",2014-06-04 14:28:00-04:00,VNDA,neutral
1318960.0,Benzinga's Volume Movers,2014-06-04 10:38:00-04:00,VNDA,neutral
1318961.0,Form 8-K from Vanda Pharma Shows Expectation for FY14 Operating Expense $110-120M,2014-06-04 07:04:00-04:00,VNDA,neutral
1318962.0,Vanda Pharmaceuticals Inc. Reports Q1 EPS of $(0.79) vs $(0.30) Est; Revenue of $9.14M vs $8.75M Est,2014-05-08 07:20:00-04:00,VNDA,neutral
1318963.0,Vanda Pharmaceuticals Announces Availability of HETLIOZ for Non-24-Hour Sleep-Wake Disorder,2014-04-09 20:08:00-04:00,VNDA,negative
1318964.0,Vanda Pharmaceutical Battles Back After Lower Open,2014-03-14 11:30:00-04:00,VNDA,negative
1318965.0,"Vanda Pharma 10-K Shows Co. Will Now Recognize Amoritization Expense of $1.7M in 2014, 2015, $1.6M in 2016",2014-02-25 07:24:00-05:00,VNDA,neutral
1318966.0,Vanda Pharmaceuticals Inc. Reports Q4 EPS of $(0.23) vs $(0.20) Est; Revenue of $8.78M vs $8.50M Est,2014-02-13 07:40:00-05:00,VNDA,neutral
1318967.0,Morning Market Losers ,2014-02-03 10:05:00-05:00,VNDA,negative
1318968.0,"Vanda Pharma Says FDA Okayed HETLIOZ for Treatment of Non-24-Hour Disorder, Sees Commercially Availability in Q2 of 2014",2014-01-31 13:46:00-05:00,VNDA,negative
1318969.0,Amended 13G from Tang Capital Partners on Vanda Pharma Shows Liquidated Position,2014-01-16 09:21:00-05:00,VNDA,neutral
1318970.0,"Option Alert: Vanda Pharmaceuticals Mar $19 Call; 6,876 Contract Trade at Bid @$0.40; Currently $12.21",2014-01-08 15:37:00-05:00,VNDA,positive
1318971.0,UPDATE: Piper Jaffray Initiates Coverage on Vanda Pharmaceuticals on Expected Attractive Returns,2013-11-27 11:29:00-05:00,VNDA,positive
1318972.0,UPDATE: Piper Jaffray Maintains Overweight On Vanda Pharmaceuticals On Hetlioz Outlook,2013-11-27 07:09:00-05:00,VNDA,negative
1318973.0,"Option Alert: Vanda Pharmaceuticals January 12 Call; 4,023 Contracts Traded vs 5 Open Interest; Currently $12.35",2013-11-19 10:04:00-05:00,VNDA,positive
1318974.0,Market Wrap For November 15: Janet Yellen's Post Fed Nomination Keeping Markets In The Green,2013-11-15 16:42:00-05:00,VNDA,neutral
1318975.0,Benzinga's Top #PreMarket Gainers,2013-11-15 08:16:00-05:00,VNDA,positive
1318976.0,US Stock Futures Rise Ahead of Economic Data,2013-11-15 07:01:00-05:00,VNDA,neutral
1318977.0,UPDATE: FDA Advisory Committee Recommends Approval of HETLIOZ,2013-11-15 06:04:00-05:00,VNDA,positive
1318978.0,Shares of Vanda Pharma Trading Up 20+% Following Resumption of Trade,2013-11-14 16:51:00-05:00,VNDA,positive
1318979.0,FDA Panel Voting 11-0 Vanda's Tasimelteon Safety Was Adequately Addressed,2013-11-14 15:03:00-05:00,VNDA,positive
1318980.0,FDA Panel Votes 10-0 Vanda Proved Hetlioz Efficacy,2013-11-14 14:58:00-05:00,VNDA,neutral
1318981.0,FDA Panel Says Vanda Presented Substantial Evidence of Hetlioz Efficacy,2013-11-14 14:57:00-05:00,VNDA,positive
1318982.0,FDA Panel Soon to Begin Voting on Efficacy of Vanda's Tasimelteon,2013-11-14 14:55:00-05:00,VNDA,neutral
1318983.0,FDA Panel Votes 10-1 Vanda's Non-24 Hour Hetlioz Has Appropriate Indication,2013-11-14 14:11:00-05:00,VNDA,neutral
1318984.0,UPDATE: Vanda Pharmaceuticals Halted for FDA Advisory Committee to Review HETLIOZ NDA ,2013-11-14 07:06:00-05:00,VNDA,neutral
1318985.0,"Vanda Pharmaceuticals Halted, Pending News",2013-11-14 07:01:00-05:00,VNDA,neutral
1318986.0,Market Wrap For November 12: Investors Continue to Speculate on the Fed's Tapering Measures ,2013-11-12 18:09:00-05:00,VNDA,neutral
1318987.0,Hearing Piper Says Anticipate Approval of Tasimelteon by January 2014,2013-11-12 09:55:00-05:00,VNDA,positive
1318988.0,UPDATE: Vanda Pharmaceuticals Rises 94% Pre-Market Vanda Pharmaceuticals as FDA Documents Say Tasimelteon is Safe and Effective Enough to Warrant Approval,2013-11-12 08:37:00-05:00,VNDA,positive
1318989.0,Vanda Rises 62% on Release of FDA Briefing Documents,2013-11-12 08:07:00-05:00,VNDA,neutral
1318990.0,"Option Alert: Vanda Pharmaceuticals December 22 Call; 3,790 Contract Trade Between Bid and Ask @$0.30",2013-11-04 11:53:00-05:00,VNDA,positive
1318991.0,"Option Alert: Vanda Pharmaceuticals November 11 Call; 4,840 Contract Trade at Ask @$1.50; Currently $7.36",2013-11-04 10:31:00-05:00,VNDA,positive
1318992.0,"Option Alert: Vanda Pharmaceuticals November $8/$13 Call Spread; 3,000 Spread Contracts Traded' Currently $7.74",2013-10-29 11:17:00-04:00,VNDA,positive
1318993.0,Lazard Capital Markets Reiterates Buy on Vanda Pharmaceuticals on Good Entry Point,2013-10-21 12:25:00-04:00,VNDA,positive
1318994.0,"Vanda Pharmaceuticals Announces FDA Advisory Committee Meeting On November 14, 2013 ",2013-10-16 16:02:00-04:00,VNDA,neutral
1318995.0,Adam Feuerstein Tweet: 'I had dinner last night w/ 1 of 2 buysiders who called $ARIA short perfectly. His next best short idea is $VNDA. FDA panel disaster Nov. 14',2013-10-10 07:15:00-04:00,VNDA,positive
1318996.0,Shares of Vanda Pharma Bouncing Off Session Lows Despite Concern Related to Novartis's Fanapt Winning Paragraph IV Patent Notification from FDA,2013-10-09 09:45:00-04:00,VNDA,positive
1318997.0,"Option Alert: Vanda Pharmaceuticals November 14 Call; 1,590 Contracts Traded @$1.30; Currently $10.18",2013-10-08 10:51:00-04:00,VNDA,positive
1318998.0,Vanda Pharmaceuticals Spikes Higher,2013-08-27 10:19:00-04:00,VNDA,neutral
1318999.0,"Vanda Shares Up Nearly 2%, Lazard Sees Odds of Positive Tasimelteon FDA Panel Vote in Nov., PDUFA in Jan. as 'Extremely High'",2013-08-13 10:33:00-04:00,VNDA,positive
1319000.0,Vanda Files To Sell 4.68 Million Shares Of Common Stock,2013-08-07 16:11:00-04:00,VNDA,positive
1319001.0,Vanda Pharmaceuticals Proposes Public Offering of Common Stock,2013-08-06 16:02:00-04:00,VNDA,neutral
1319002.0,"Jefferies Maintains Buy on Vanda Pharmaceuticals Inc., Raises PT to $14.00",2013-08-01 09:22:00-04:00,VNDA,neutral
1319003.0,Report Vanda Paid Regulatory Consultant $500K -TheStreet.com,2013-07-31 09:09:00-04:00,VNDA,neutral
1319004.0,Vanda Pharmaceuticals Inc. Reports Q2 EPS of $(0.11) vs $(0.22) Est; Revenue of $8.30M vs $8.43M Est,2013-07-31 06:55:00-04:00,VNDA,neutral
1319005.0,UPDATE: Jefferies Raises PT on Vanda Pharmaceuticals Following FDA Decision,2013-07-30 10:43:00-04:00,VNDA,neutral
1319006.0,"Jefferies Maintains Buy on Vanda Pharmaceuticals Inc., Raises PT to $13.00",2013-07-30 07:28:00-04:00,VNDA,neutral
1319007.0,Vanda Announces FDA Accepts Tasimelteon NDA for Priority Review in Treatment of Non-24-Hour Disorder in the Totally Blind ,2013-07-29 22:13:00-04:00,VNDA,negative
1319008.0,"Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In Vanda Pharmaceuticals, Inc. To Contact The Firm",2013-06-25 17:00:00-04:00,VNDA,negative
1319009.0,"Jefferies Maintains Buy on Vanda Pharmaceuticals Inc., Raises PT to $11.00",2013-06-20 08:55:00-04:00,VNDA,neutral
1319010.0,"With Shares of Vanda Down 21+% Following Negative The Street Article, Lazard Tells Investors to Buy the Dip, Cites Confidence for FDA Approval by Vanda Mgmt",2013-06-19 15:24:00-04:00,VNDA,positive
1319011.0,Afternoon Market Losers,2013-06-19 12:38:00-04:00,VNDA,negative
1319012.0,Morning Market Losers ,2013-06-19 10:10:00-04:00,VNDA,negative
1319013.0,Benzinga's Top Pre-Market Losers,2013-06-19 08:18:00-04:00,VNDA,negative
1319014.0,Vanda Shares Fall 15% Pre-Market on Negative Adam F Article on Tasimelteon -TheStreet,2013-06-19 08:13:00-04:00,VNDA,negative
1319015.0,Vanda Presents Positive Data from Phase 3 Tasimelteon Study,2013-06-17 20:00:00-04:00,VNDA,positive
1319016.0,Benzinga's Volume Movers,2013-06-11 11:22:00-04:00,VNDA,neutral
1319017.0,Stocks Hitting 52-Week Highs,2013-06-11 11:06:00-04:00,VNDA,neutral
1319018.0,"Vanda Pharmaceuticals Rises 11%, Baker Bros Reported 14% Stake on Monday",2013-06-11 09:45:00-04:00,VNDA,neutral
1319019.0,Benzinga's Top Pre-Market Gainers,2013-06-11 08:14:00-04:00,VNDA,positive
1319020.0,Vanda Pharmaceuticals Moves Higher; May be Attributed to Positive CNBC Comments,2013-06-04 14:20:00-04:00,VNDA,positive
1319021.0,Lazard Adds Vanda Pharma to 'Fresh Money Ideas' List,2013-06-03 08:59:00-04:00,VNDA,positive
1319022.0,A Peek Into The Market Before The Trading Starts,2013-05-31 07:20:00-04:00,VNDA,neutral
1319023.0,Vanda Announces Submits NDA to FDA for Tasimelteon forTreatment of Non-24-Hour Disorder in the Totally Blind,2013-05-31 06:58:00-04:00,VNDA,negative
1319024.0,UPDATE: Lazard Has a Buy on Vanda with a $17 PT,2013-05-24 10:45:00-04:00,VNDA,neutral
1319025.0,Vanda CFO Says Strength May be Attributed to Positive Lazard Note,2013-05-24 10:41:00-04:00,VNDA,positive
1319026.0,"Top Performing Industries For May 17, 2013",2013-05-17 10:35:00-04:00,VNDA,positive
1319027.0,Morning Market Movers ,2013-05-17 09:59:00-04:00,VNDA,neutral
1319028.0,Stocks Hitting 52-Week Highs ,2013-05-13 11:02:00-04:00,VNDA,neutral
1319029.0,Vanda Pharmaceuticals Inc. Reports Q1 EPS of $(0.15) vs $(0.25) Est; Revenue of $8.07M vs $8.42M Est,2013-05-09 07:51:00-04:00,VNDA,neutral
1319030.0,Form 8-K Shows Vanda Reported Bristol-Myers Waived Options on Tasimelteon,2013-04-29 07:31:00-04:00,VNDA,neutral
1319031.0,Vanda Pharmaceuticals Names Dr. Paolo Baroldi CMO,2013-04-17 19:40:00-04:00,VNDA,neutral
1319032.0,Vanda Withdraws Its Marketing Authorization Application For Fanaptum In The European Union,2013-03-14 16:07:00-04:00,VNDA,neutral
1319033.0,UPDATE: Piper Jaffray Initiates Vanda Pharmaceuticals with Overweight on Tasi' Potential,2013-03-06 08:50:00-05:00,VNDA,negative
1319034.0,"Piper Jaffray Initiates Coverage on Vanda Pharmaceuticals Inc. at Overweight, Announces $8.00 PT",2013-03-05 16:08:00-05:00,VNDA,negative
1319035.0,UPDATE: Jefferies Upgrades Vanda Pharmaceuticals to Buy on Tasimelteon Catalyst,2013-02-14 07:55:00-05:00,VNDA,neutral
1319036.0,"Jefferies Upgrades Vanda Pharmaceuticals Inc. to Buy, Raises PT to $6.00",2013-02-14 06:20:00-05:00,VNDA,neutral
1319037.0,Vanda Pharmaceuticals Inc. Reports Q4 EPS of $(0.23) vs $(0.18) Est; Revenue of $7.90M vs $8.40M Est,2013-02-12 07:02:00-05:00,VNDA,neutral
1319038.0,"Lazard Initiated Coverage on Vanda Pharma with a Buy Rating, $11 Price Target, Neurocrine Biosciences with a Buy and $13 PT, Repros Therapeutics with Buy, $26 PT",2013-02-05 10:12:00-05:00,VNDA,neutral
1319039.0,A Peek Into The Market Before The Trading Starts,2013-01-23 07:13:00-05:00,VNDA,neutral
1319040.0,Vanda Announces Positive Phase III Study Results for Tasimelteon for Treatment of Non-24-Hour Disorder ,2013-01-23 06:45:00-05:00,VNDA,positive
1319041.0,Benzinga's Top Initiations,2013-01-17 07:50:00-05:00,VNDA,positive
1319042.0,"Benzinga's Small Cap Movers for Tuesday December 18, 2012 ",2012-12-18 22:20:00-05:00,VNDA,neutral
1319043.0,Morning Market Movers,2012-12-18 10:02:00-05:00,VNDA,neutral
1319044.0,Vanda Announces Positive Results from Tasimelteon Phase III Study,2012-12-18 07:11:00-05:00,VNDA,positive
1319045.0,Vanda Announces Negative Opinion from CHMP on Fanaptum for the Treatment of Schizophrenia ,2012-12-13 22:26:00-05:00,VNDA,negative
1319046.0,"Jefferies & Company Maintains Vanda Pharmaceuticals at Hold, Lowers PT from $4.50 to $3.50",2012-11-08 07:28:00-05:00,VNDA,negative
1319047.0,Vanda Pharmaceuticals Reports Tasimelteon Restores Daily Cortisol Rhythms in Blind Patients,2012-10-15 07:16:00-04:00,VNDA,negative
1319048.0,Vanda Pharmaceuticals Reports Q2 EPS $-0.28 vs $-0.27 Est; Revenues $8.38M vs $8.30M Est,2012-08-02 08:43:00-04:00,VNDA,neutral
1319049.0,Vanda Pharmaceuticals Acquires Rights to NK-1 Receptor Antagonist from Eli Lilly and Company ,2012-04-16 07:00:00-04:00,VNDA,negative
1319050.0,Beware of Sofia Vergara-like stocks,2012-04-10 15:49:00-04:00,VNDA,neutral
1319051.0,Benzinga's Top Downgrades,2012-03-13 07:32:00-04:00,VNDA,positive
1319052.0,UPDATE: Jefferies Downgrades Vanda Pharmaceuticals to Hold,2012-03-13 07:19:00-04:00,VNDA,neutral
1319053.0,"Jefferies & Company Downgrades Vanda Pharmaceuticals from Buy to Hold, Lowers PT from $8.5 to $4.5",2012-03-13 06:07:00-04:00,VNDA,negative
1319054.0,Vanda Pharmaceuticals Reports Q4 EPS $(0.20) vs $(0.19) Est; Revenues $8.40M vs $8.20M Est	 		,2012-02-14 07:06:00-05:00,VNDA,neutral
1319055.0,Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Megapharm for Commercialization of Fanapt in Israel  ,2011-12-13 07:07:00-05:00,VNDA,positive
1319056.0,Disclosure Insight Maintains Medium Risk Rating on Vanda Pharmaceuticals ,2011-11-11 07:16:00-05:00,VNDA,negative
1319057.0,"Jefferies Reiterates Buy on Vanda Pharmaceuticals, Reduces PT to $8.50",2011-08-08 07:46:00-04:00,VNDA,neutral
1319058.0,Jefferies Lowers PT On Vanda Pharmaceuticals To $8.50,2011-08-08 06:46:00-04:00,VNDA,negative
1319059.0,Vanda Pharmaceuticals Reports Q2 EPS $(0.05) vs $(0.05) Est; Revenues $7.4M vs $8.07M Est	,2011-08-04 07:18:00-04:00,VNDA,neutral
1319060.0,Vanda Pharmaceuticals Enters into an Exclusive License Agreement with Biotoscana Farma S.A. for Commercialization of Fanapt  in Argentina.,2011-08-01 07:03:00-04:00,VNDA,positive
1319061.0,European Medicines Agency Accepts Vanda Pharmaceuticals Inc.'s Marketing Authorization Application For Oral Iloperidone Tablets,2011-07-26 07:08:00-04:00,VNDA,positive
1319062.0,Vanda Pharmaceuticals Announces Exclusive License Agreement with Probiomed for Commercialization of Fanapt in Mexico ,2011-07-11 07:06:00-04:00,VNDA,positive
1319063.0,"Hapoalim Securities Terminates Healthcare Coverage Including Bristol-Myers, Eli Lilly, Merck and Pfizer",2011-06-01 12:13:00-04:00,VNDA,positive
1319064.0,Hapoalim Cutting Ocverage On Multitude Of Names,2011-06-01 11:48:00-04:00,VNDA,negative
1319065.0,"List of Seven Cheap Biotech Stocks Expected to Grow, Seeking Alpha Reports (CHTP, TLON, HGSI, VNDA, OREX, SNTA, VICL) ",2011-04-28 15:16:00-04:00,VNDA,neutral
1319066.0,"Hapoalim Securities Reiterates Buy Rating, $15 PT On VNDA",2011-04-12 08:11:00-04:00,VNDA,positive
1319067.0,A Peek Into The Market Before The Trading Starts,2011-03-31 07:20:00-04:00,VNDA,neutral
1319068.0,Vanda Pharmaceuticals to Evaluate Tasimelteon in Major Depression ,2011-03-31 07:12:00-04:00,VNDA,negative
1319069.0,UPDATE: Jefferies Color On VNDA Q4,2011-02-11 10:52:00-05:00,VNDA,neutral
1319070.0,Jefferies Lowers PT On Vanda Pharmaceuticals To $10,2011-02-11 08:47:00-05:00,VNDA,negative
1319071.0,Hapoalim Securities Lowers VNDA Target To $15 From $16,2011-02-07 09:51:00-05:00,VNDA,positive
1319072.0,Vanda Pharmaceuticals Falling On Disappointing Drug Sales (VNDA),2011-02-04 12:21:00-05:00,VNDA,negative
1319073.0,Vanda Pharmaceuticals Files to Sell $50M of Common Stock ,2011-01-31 07:52:00-05:00,VNDA,neutral
1319074.0,Hapoalim Securities Decreases VNDA Estimates,2011-01-19 10:20:00-05:00,VNDA,positive
1319075.0,10 Unloved Stocks to Rise Up to 120%,2010-12-16 06:30:00-05:00,VNDA,negative
1319076.0,Hapoalim Increases Vanda PT To $16,2010-11-15 10:43:00-05:00,VNDA,neutral
1319077.0,Vanda Pharmaceuticals Pops 7% on IRS Ruling (VNDA),2010-11-15 10:05:00-05:00,VNDA,neutral
1319078.0,Vanda Pharmaceuticals Appoints Chief Financial Officer,2010-11-12 07:25:00-05:00,VNDA,neutral
1319079.0,Vanda Pharmaceuticals Soars On Earnings Beat (VNDA),2010-11-03 13:58:00-04:00,VNDA,neutral
1319080.0,Hapoalim Securities Reiterates Buy Rating on Vanda Pharma (VNDA),2010-11-03 12:05:00-04:00,VNDA,positive
1319081.0,Vanda Pharmaceuticals Reports Prescription All Time High,2010-10-05 07:54:00-04:00,VNDA,neutral
1319082.0,Vanda's Pipeline Progresses - Analyst Blog,2010-08-27 18:03:00-04:00,VNDA,neutral
1319083.0,"Hapoalim Lowers Price Target On Vanda, Reiterates Buy (VNDA)",2010-08-05 15:14:00-04:00,VNDA,negative
1319084.0,Hapoalim Securities Reiterates Buy Rating on Vanda Pharma (VNDA),2010-05-28 09:42:00-04:00,VNDA,positive
1319085.0,"Benzinga’s Top Pre-Market Losers (OPWV, GMCR, VNDA, ASMI, ZN)",2010-04-29 09:05:00-04:00,VNDA,negative
1319086.0,"Benzinga’s Top Pre-Market Losers (OPWV, GMCR, VNDA, ASMI, ZN)",2010-04-29 09:05:00-04:00,VNDA,negative
1319087.0,"Benzinga's After Hours Gainers (KEY, VANDA, NKTR)",2010-04-06 18:07:00-04:00,VNDA,neutral
1319088.0,How Will Obama-Care Play Into The Markets And ETFs?,2010-03-21 21:50:00-04:00,VNDA,positive
1319089.0,Volume Talks Wednesday March 10: Two Option Ideas on One Hot Stock,2010-03-11 09:32:00-05:00,VNDA,neutral
1319090.0,"Benzinga’s Volume Movers (FACT, ITMN, VNDA, BONT, HRBN)",2010-03-10 14:49:00-05:00,VNDA,neutral
1319091.0,VNDA Misses Q4 Expectations On Novartis Deal Related Costs,2010-02-17 11:41:00-05:00,VNDA,negative
1319092.0,"Benzinga’s Top Pre- Market Gainers (HITK, NLST, RMBS, SQNM, VNDA, AVNR)",2009-12-09 08:55:00-05:00,VNDA,positive
1319093.0,"Pre-Market Top Movers (HITK, RMBS, VNDA)",2009-12-09 08:28:00-05:00,VNDA,positive
1319094.0,"This Year’s Top Percentage Gainers (DDRX, SCSS, DTG, VNDA, CAR)",2009-10-09 07:50:00-04:00,VNDA,positive
1319095.0,"Stock Watch:  TTNP, VNDA, DNDN, AGEN, ONTY",2009-08-17 16:44:00-04:00,VNDA,neutral
